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Abstract
Purpose. To study the evolution of concepts concerning gastrointestinal stromal tumours (GISTs) over 30 years.
Discussion. GISTs have been, for more than 30 years, the subject of considerable controversy regarding their line of
differentiation as well as the prediction of their behaviour. Furthermore, once they spread within the peritoneal cavity, they
are extremely hard to control. The recent ® ndings of c-Kit mutations and the immunohistochemical detection of the
product of this gene, KIT or CD117, in the mainly non-myogenic subset of this family of tumours, has led to a reappraisal
of this group of lesions, which, with some exceptions, is now thought to be derived from the interstitial cells of Cajal, and
this has facilitated a clearer de® nition of their pathological spectrum. In this article, we review chronologically the evolution
of the concept of GIST with the gradual application of electron microscopy, immunohistochemistry, DNA ploidy analysis.
We discuss the impact of these techniques on the pathological assessment and clinical management of GISTs.
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Introduction
Neoplasms arising from the stromal (or mural) com-
ponents of the gut can be broadly divided into two
categories. Some tumours are not unique to the
gastrointestinal wall and appear similar to their
counterparts in other locations. This category in-
cludes schwannomas, usual leiomyomas (mostly lo-
cated in the oesophagus and rectal wall) and
leiomyosarcomas, showing characteristic morpho-
logical, immunohistochemical and ultrastructural
features of smooth muscle differentiation, as well as
some uncommon neoplasms such as lipomatous and
vascular tumours. The other category is composed
of spindle and epithelioid neoplasms histologically
resembling smooth muscle tumours but either lack-
ing or presenting only limited immunohistochemical
and ultrastructural features of myogenic, neural or
neuronal differentiation, for which prediction of
behaviour has proved to be problematic.
Stromal tumours of the gastrointestinal tract
(GIST) occur over a wide age range but affect
predominantly middle-aged and elderly individuals,
with a slight female predominance. Bleeding is the
most common initial symptom, and up to 20% of
patients present with anemia. Pain represents an-
other common complaint. Despite their large size,
only a small proportion of tumours are palpable.
1
The biological behaviour of GISTs is dif® cult to
determine accurately from data available in the
literature, given the different morphological and di-
agnostic criteria used, and the tendency for late
metastases, in some cases, with spread sometimes
occurring after 20 to 30 years.
2 The overall 5 and
10-year survivals of malignant GISTs, have been
estimated at between 25 and 50%,
3,4 although in
one series, only 10% of patients remained free of
disease after a median follow-up of 68 months.
3
Most such patients succumb to disseminated in-
traabdominal disease (with metastasis to the omen-
tum, mesentery, peritoneum and liver), although
distant metastases (mainly to the lungs and bone)
occasionally occur.
5,6 Treatment of GIST is essen-
tially surgical and the type of operation has been
shown to represent one of the most important deter-
minants of survival.
3 Surgical excision of intraab-
dominal metastases has also been shown to slightly
improve survival.
6 Unfortunately, GISTs tend to
respond poorly to chemotherapy, being even less
chemosensitive than leiomyosarcomas at other
sites.
7,8
Despite their relative rarity when compared to
epithelial tumours in this anatomical location, these
tumours, usually grouped under the non-committal
term of gastrointestinal stromal tumour (GIST),
have been one of the most controversial subjects in
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the recent pathology literature. Until this year, the
large number of studies generated by the progressive
use of electron microscopy, immunohistochemistry,
¯ ow cytometry and proliferation markers have
mostly provided contradictory or inconclusive re-
sults regarding the `histogenesis’ of these tumours
and determination of their prognosis.
The recent identi® cation of mutations of the c-Kit
gene in GISTs,
9 and the immunohistological detec-
tion of its product, KIT or CD117,
9± 11 suggesting
differentiation towards the phenotype of the inter-
stitial cell of Cajal,
9,10 has served as the basis for a
new de® nition of GISTs, and has provided an ele-
gant explanation for the previously controversial re-
sults relating to the phenotype of these tumours, as
well as a new springboard for future investigations.
In this article, using a chronological approach, we
review the evolution of the `concept’ of GISTs, from
Stout’s early reports to the most recent studies,
mentioned above, and discuss the impact of these
developments on our understanding of GISTs,
based on the literature and our personal experience.
Histogenesis/differentiation
GISTs were originally thought to arise from mural
smooth muscle of the gastrointestinal tract, based
on their histological resemblance to leiomyomas and
leiomyosarcomas at other sites, as well as their usu-
ally intimate association with the wall of the gut.
12± 14
Epithelioid tumours, ® rst identi® ed by Martin
et al.
15 and subsequently popularised by Stout,
16
were also considered to be smooth muscle neo-
plasms on the basis of the transition between spindly
and epithelioid areas in some lesions. Subsequently,
some authors noticed morphological differences be-
tween these `leiomyomas’ and `leiomyosarcomas’ of
the gastrointestinal tract and their counterparts in
other sites: most gastrointestinal lesions appeared
more cellular and the tumour cells had more elon-
gated nuclei and less brightly eosinophilic cyto-
plasm. However, most authors attributed this to a
relative lack of differentiation, rather than to the
possibility of alternative lines of differentiation. In
addition, it rapidly became clear that GISTs, unlike
their apparent counterparts in other sites, could
metastasise despite the absence of usual histological
features of malignancy (in particular, in the absence
of signi® cant mitotic activity) and that their behav-
iour was much harder to predict.
12,14,17
Ultrastructural studies
The 1970s and the early 1980s saw the debate
concerning these lesions focusing on the ultrastruc-
tural features of gastrointestinal sarcomas, of which
the presumed smooth muscle differentiation had
started to be questioned. In 1969, in their ultra-
structural study of three ª gastric cellular leiomy-
omasº , Welsh and Meyer noticed that ultra-
structural features of smooth muscle (i.e. cyto-
plasmic ® laments with dense bodies, extracellular
basement membrane, pinocytic vesicles) were
identi® ed in only occasional cells and were often
incomplete.
18 These results were con® rmed by most
subsequent studies, which failed to identify
myo® laments with focal densities in most tumours;
in fact, smooth muscle differentiation in gastrointes-
tinal stromal tumours was most often supported
only by relatively non speci® c features (such as the
presence of pinocytic vesicles or focal basal lam-
ina).
19± 23 In addition, several authors started to
identify Schwannian or neuroaxonal characteristics,
in some cases microscopically indistinguishable
from other GISTs,
21,22,24 and in 1984, a distinctive
subset of tumours, showing features of autonomic
neural differentiation was ® rst described.
25
Immunohistochemical studies
The introduction of immunohistochemistry, in the
1980s, strengthened the debate relating to the dif-
ferentiation of GISTs and initiated a profusion of
publications.
22,26± 34 Numerous series of GIST have
been decorated with diverse antibodies with incon-
sistent results. Although a large proportion (between
30 and 80%) of GISTs have been shown to express
muscle markers,
29,33,34 the most speci® c of these,
desmin, has usually stained only a minority of tu-
mours.
30,33 Variable proportions of tumours with a
neural phenotype have been identi® ed (from none
to approximately 40%)
29,30,33 and, interestingly, di-
vergent differentiation (coexpression of muscular
and neural markers) was identi® ed in up to 20% of
cases by Newman et al.
29 Up to 41% of tumours
have been characterised by a `null’ or `uncommitted’
phenotype, being stained by vimentin only.
27 More
recently, CD34, initially identi® ed as a myeloid cell
progenitor antigen, but also expressed in endothelial
cells, in some mesenchymal cells as well as in a
variety of soft tissue neoplasms, has been shown to
stain up to 80% of GISTs, with or without markers
of other speci® c differentiation.
35± 37
Several reasons may explain the striking lack of
consistency of these results, which has rendered
their interpretation particularly dif® cult. Technical
issues, relating to the nature of ® xative, duration of
® xation, nature and dilution of antibodies are cer-
tainly partly responsible for some of these discrepan-
cies. Variable thresholds for positivity may have
been used and the presence of normal neural ele-
ments or muscle bundles may have caused some
problems in interpretation. For example, in Mazur’s
study, ® rst reporting S100 protein immunopositivity
in GISTs, seven of eight S100-positive tumours
contained only scattered elements which may be
more in keeping with entrapped structures than with
true nerve sheath differentiation.
22 Variable criteria
for smooth muscle and neural differentiation have
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have assessed neural differentiation in GISTs using
only antibodies for S100 protein, others have em-
ployed a combination of more or less speci® c
markers including NSE, PGP9.5 or Leu7.
Several authors have tried to correlate the im-
munophenotype of GISTs with tumour location,
histological appearance and, more importantly, with
prognosis. No signi® cant differences have been
demonstrated in terms of immunophenotype be-
tween epithelioid and spindle cell lesions. In fact, no
reliable correlation between the histological features
of GIST and their immunophenotype has been
achieved.
27,29 Regarding the relationship with tu-
mour site, the observation that, in contrast to most
gastric and intestinal tumours, oesophageal and
rectal tumours frequently fail to stain for CD34 and
tend to express desmin, has represented an interest-
ing ® nding, indicating that these tumours likely
represent `true’ smooth muscle tumours that should
be differentiated from GISTs, which rarely occur in
these locations. Some differences in immunopheno-
type between gastric and intestinal tumours, the
latter tending to more commonly express a neural
phenotype, have also been suggested
29,33,38 but have
not been further investigated.
The possible relationship between the im-
munophenotype and prognosis has represented one
of the more controversial issues in GISTs. Results of
a few studies have suggested the possibility of differ-
ences in prognosis between immunophenotypic sub-
sets: it has been proposed that tumours with a
neural
4,29 or smooth muscle
29 phenotype tend to
have a better prognosis, while those with a null
phenotype seem more often to behave in a malig-
nant fashion.
34 However, these results have not been
con® rmed and this ® eld of investigation has gradu-
ally been abandoned, on the basis of the consistently
inconclusive and variable results. In consequence,
many pathologists have stopped phenotyping GISTs
in their routine practice. We believe that in the
absence of de® nitive results, the line of differen-
tiation should continue to be part of the information
provided to the clinician in any case of GIST and to
be included in future studies, until de® nitely proven
irrelevant (or otherwise). In larger studies, the phe-
notype of GISTs might not only prove to carry some
prognostic signi® cance but could also possibly show
some relation with treatment response, as, for exam-
ple, it is well known that leiomyosarcomas at other
sites do not usually respond well to chemotherapy.
Gastrointestinal autonomic nerve tumours (GANT)
Among the spectrum of GISTs, speci® c attention
has been given in recent years to those showing
autonomic neural differentiation. These tumours
were described in 1984 by Herrera et al.
25 as
`plexosarcomas’, and subsequently designated gas-
trointestinal autonomic nerve tumour (GANT).
39
Although they tend to be composed of syncytial
sheets of cells characterised by distinctive ® brillary
eosinophilic cytoplasm, commonly associated with
stromal lymphocytes and extracellular nodules of
eosinophilic material known as `skeinoid ® bers’,
40
their histological spectrum is wide and it is largely
accepted that accurate diagnosis is based on ultra-
structural criteria, i.e. long cytoplasmic processes
with rudimentary cell junctions and synapse-like
structures containing dense-core granules.
41 Im-
munohistochemically, these lesions often show posi-
tivity for NSE, usually in a peculiar `zoning pattern’
and, interestingly, they are generally negative for
CD34
42 (personal observations). Although these tu-
mours have been the subject of an increasing num-
ber of publications,
25,39,41± 48 the relative frequency of
GANT and its relationship with other GISTs still
requires clari® cation. At the present time, there is
no convincing evidence that these tumours differ
signi® cantly from other GISTs in terms of either
their clinical presentation or behaviour. Neverthe-
less, further investigations will be required to deter-
mine if criteria for malignancy can be established
and whether they differ from those applied in other
GISTs.
Prediction of behaviour
The dif® culty in classifying GISTs into benign and
malignant categories has been recognised since the
description of `smooth muscle tumours’ of the gut,
by Golden and Stout in 1941, who noted that
tumours showing usual histological criteria of malig-
nancy did not consistently behave aggressively,
while occasional well differentiated low-grade le-
sions gave rise to metastases.
12 In a series of 87
GISTs, Kempson and Ranchod identi® ed the mi-
totic count as the most useful indicator of malig-
nancy. However, while the presence of 5 or more
mitoses per 10 HPF was closely correlated with
aggressive behaviour, 40% of `leiomyosarcomas’ had
fewer mitotic ® gures.
14 In order to re® ne the separ-
ation of benign and malignant GISTs, a profusion
of studies subsequently analysed the correlation
between malignancy and various clinical and patho-
logical parameters, often with variable re-
sults.
1,4,29,32,34,49± 52
The mitotic count has been most widely accepted
as the best prognostic indicator
1,5,14 and it has been
shown that, among clinically malignant tumours, a
high mitotic count was associated with a shorter
disease free interval and shortened overall survival.
5
Various cutoff levels, separating GISTs into benign
and malignant categories, sometimes including a
`borderline category’, or into low and high-grade
subsets have been proposed.
5,51,53,54 However, be-
cause of the overlap in terms of mitotic activity
between clinically benign and malignant GISTs,
and in view of the rare occurrence of metastasis in
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none of these has proven entirely reliable in the
management of individual patients.
The extent of disease at diagnosis (or stage) cer-
tainly also represents a strong indicator of outcome.
While the presence of metastases at presentation,
not surprisingly, is associated with a very poor prog-
nosis, in® ltration of adjacent structures, such as the
liver, pancreas or diaphragm, is also usually re-
garded as indicative of malignancy. In Shiu’s study,
all tumours which invaded adjacent organs led to
the patient’s death.
50 Tumour size has also been
shown to be strongly correlated with the occurrence
of metastases. In Appelman’s series of 127 cases,
only one tumour smaller than 6 cm metastasised.
17
These results have been con® rmed by most studies
and, again, various cutoff levels have been proposed,
usually being set at around 5± 6 cm. Unfortunately,
as for the mitotic count, some exceptions have been
encountered, and, tumours as small as 2 cm have
been reported to metastasise.
5 In relation to tumour
size, it is interesting to note that tumours found
incidentally during operation performed for another
unrelated condition usually carry an excellent prog-
nosis; in the study of Cooper et al. none of 19
incidentally discovered tumours resulted in the pa-
tient’s death.
51
In order to re® ne this discrimination between
malignant and benign lesions, numerous other clini-
cal, macroscopic and histological parameters have
been assessed, most of which have been shown,
at least in some univariate studies, to have some
correlation with survival or the development of
metastases. Cellularity has been considered useful
by several authors,
4,12,14,38,51,55 but this is extremely
subjective and dif® cult to quantitate, and thus is
subject to a signi® cant interobserver variability.
Moreover, its interpretation is complicated by the
variability between areas of the same tumour.
Although the presence of unequivocal tumour cell
necrosis is usually regarded as highly suspicious for
malignancy, this has been reported in rare clinically
benign cases.
55 Ulceration of the overlying mucosa
has also been considered as a worrisome feature by
some authors.
38,55,56 The presence of atypical mi-
toses has been shown in some studies to be strongly
associated with malignancy
52 but the utility of this
feature is limited by the fact that abnormal mitotic
® gures are rarely encountered in GISTs to the point
that, in our experience, a diagnosis of GIST is
improbable in the presence of conspicuous abnor-
mal mitoses.
Potential differences in terms of behaviour be-
tween epithelioid and spindle cell lesions has been
another controversial topic; while most studies have
not shown any correlation between cell type and
prognosis, a few recent studies have suggested that
epithelioid lesions tend to behave more often in a
malignant fashion.
29,38,56 In the study of Newman et
al. all malignant gastric tumours contained at least
some foci composed of epithelioid cells, justifying
their more cautious criteria for malignancy in ep-
ithelioid GISTs.
29
Aside from oesophageal and colorectal tumours,
which usually display fully developed features of
smooth muscle differentiation (and therefore can be
excluded, at least conceptually, from the GIST
spectrum), signi® cant differences in terms of out-
come according to tumour site have only been ob-
served in one study, in which the ten year survival
reached 74% for gastric lesions, while it was only
17% for small bowel tumours.
32 In fact, during the
last three years, a few studies have analysed prog-
nostic factors in selected populations of tumours
from speci® c sites, such as the duodenum but,
again, have not been able provide de® nitive criteria
for malignancy.
38,55,56
Interestingly, some studies have shown a better
prognosis in rare pediatric cases and in young
adults, with long survival despite metastatic dis-
ease.
57 In fact, most of these patients appear to be
affected by Carney’s triad. In this syndrome, of
which the genetic basis is still unclear, patients tend
to develop gastric epithelioid `leiomyosarcomas’,
functioning extraadrenal paragangliomas and pul-
monary chondromatous hamartomas (which are
sometimes clinically and radiologically misinter-
preted as metastases from the gastrointestinal tu-
mours). These tumours usually appear at a relatively
young age and prolonged survival (more than 20
years) is commonly observed in the presence of
metastases, even without surgical treatment.
Ploidy and proliferation markers
Because of this imperfect separation between benign
and malignant GISTs using conventional pathologi-
cal criteria, as well as the subjectivity and/or interob-
server variability in the evaluation of some of these
parameters, ancillary techniques such as the evalu-
ation of ploidy (by DNA ¯ ow cytometry or comput-
erised image analysis) and proliferation markers
were introduced with enthusiasm in the early 1990s.
Most studies have suggested that DNA ploidy, de-
termined by ¯ ow cytometry, was signi® cantly corre-
lated with histological grading and that aneuploidy
was associated with decreased survival.
4,51,53,58 How-
ever, most of these authors compared tumour ploidy
with malignancy de® ned either clinically but with a
limited follow-up or de® ned only by histological
criteria. A subsequent study, validated by 6 years
median follow-up, demonstrated that ploidy lost its
prognostic value in a multivariate model, which
included mitotic count and the presence or absence
of metastases at diagnosis.
52 Moreover, most of
these studies included aneuploid cases that did not
show clinical evidence of malignancy and, more
importantly, a few patients with diploid tumours
(even of small size), developed disseminated dis-
ease.
4,52 Because of this overlap, ploidy does not
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Table 1. Histological criteria for grading gastrointestinal stromal tumours
Benign 0± 2 mitoses/30 HPF spindle cell lesion, no atypia
or
0 mitoses/30 HPF epithelioid lesion
Borderline 2± 3 mitoses/30 HPF spindle cell lesion, mild plomorphism/hyperchromasia
or
3± 4 mitoses/30 HPF spindle cell lesion, no atypia
or
1 mitosis/30 HPF epithelioid lesion
Malignant $ 5 mitoses/30 HPF spindle cell lesion, no atypia
or
$ 3 mitoses/30 HPF spindle cell lesion, frank pleomorphism/hyperchromasia
or
$ 2 mitosis/30 HPF epithelioid lesion
individual cases, even if some correlation with
prognosis can be shown at the statistical level.
Immunoreactivity for proliferating cell nuclear
antigen (PCNA), and interphase nucleolar organiser
regions (AgNOR) counts have also encountered
variable success. While some authors failed to show
any correlation between PCNA index and mitotic
rate, tumour size or behaviour,
54 most other studies
indicated a statistically signi® cant relationship with
survival in univariate analysis.
4,59± 61 However, once
again, the PCNA index, in multivariate analysis, did
not appear to provide any improvement over the
mitotic count in the prediction of metastatic
spread
62 and it was shown (by Yu et al.) to be less
reliable than histological grading using the scheme
proposed in Table 1.
61
Therefore, even if these `modern methods’ can be
somehow correlated with survival or with the proba-
bility of developing metastases, from a statistical
point of view, no signi® cant advantage has been
demonstrated over a careful mitotic count or histo-
logical grading. The clinical value of these tech-
niques in individual uses is also limited, as is the
case for traditional pathological criteria, by a degree
of overlap between benign and malignant tumours.
Although these proliferative indices may be helpful
in some `borderline’ cases, and have been intro-
duced in some classi® cation systems,
60 their use is
not warranted in the routine evaluation of GISTs at
the present time.
Practical recommendations
It appears clear from the previous discussion that, at
this point, published data available concerning phe-
notypic classi® cation and prognosis are extremely
controversial and somewhat confusing. Many rea-
sons may have contributed to the heterogeneity of
previous results. Most series are relatively small and,
in statistical terms, do not include enough cases
covering the different parameters assessed, as well as
the different locations and immunophenotypes. Fol-
low up is probably too short in the context of the
biology of these neoplasms, given that late metas-
tases, sometimes occurring after more than 20 or 30
years, are not uncommon. The de® nitions of malig-
nancy, and in fact, the methodology have varied
widely between studies. Most groups have strati® ed
tumours according to histological criteria into cate-
gories (benign, uncertain potential, malignant) that
they have then compared with clinical behaviour. In
fact, a potentially more rational approach, consisting
of classifying tumours according to their behaviour,
after adequate follow-up, and then analysing their
clinicopathological characteristics, has not been ap-
plied in any large series. De® nitions of GIST have
also varied widely between authors. Some authors
have included typical cases of schwannomas, as well
as conventional leiomyomas, thus introducing selec-
tion bias, while others have chosen to exclude all
cases positive for muscle markers, or to exclude
those which were negative for CD34.
Because of the unreliability of available criteria
(when applied individually) in distinguishing tu-
mours likely to behave in a benign or malignant
fashion, multifactorial approaches have been at-
tempted. A wide variety of prognostic schemes,
including different parameters and varying accord-
ing to tumour location, have been proposed. Actu-
ally, almost every single author has proposed his or
her own classi® cation scheme and, at the present
time, none has proven superior to the others. For
practical purposes, we personally use the criteria set
out in Table 1. This table, established on the basis
of personal experience and of relatively simple use,
has proven useful in our daily practice and has
appeared more reliable than any marker of prolifera-
tion.
61 However, other schemes, such as those pre-
sented by Suster in his review article,
63 have proven
useful and, of course, they should also be
considered.
It seems clear that larger series, with reproducible
diagnostic and prognostic criteria, prolonged follow-
up, including cases from various sites and covering
a large number of parameters need to be collected.
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use one scheme (such as that in Table 1), and that
the inevitable uncertainty which presently exists
concerning the behaviour of some GISTs, for exam-
ple in the case of histologically benign but large
tumours, should be expressed in the pathology
report.
Recent developments
C-Kit is a proto-oncogene encoding a transmem-
brane tyrosine-kinase receptor, KIT or CD117.
64
The interaction of this receptor with its ligand, the
stem cell factor (SCF), has been shown to play an
important role in the development of melanocytes,
germ cells, mast cells and the interstitial cells of
Cajal (ICCs).
65,66 The latter, which are located be-
tween the muscular layers of the gastric and intesti-
nal wall in association with the myenteric plexus, are
known to regulate the autonomous contraction of
the gastrointestinal tract.
67,68 These cells are charac-
terised immunohistochemically by dual im-
munopositivity for CD34 and CD117. Recently, the
hypothesis that GISTs might differentiate towards
an ICC phenotype, which had already been raised
by Mikhael et al. on the basis of their immunoposi-
tivity for CD34,
36 has been supported by three
immunohistochemical, ultrastructural and molecu-
lar studies.
9± 11 These groups have demonstrated that
immunoreactivity for CD117 was seen in 85± 100%
of GISTs while most other sarcomas or other neo-
plasms were negative. In addition, the sequencing of
c-Kit complementary DNA revealed mutations in 5
of 6 cases from one of these series and our own
personal experience with larger case numbers
(Rubin et al., unpublished data) is similar.
These studies included spindle cell and epithe-
lioid neoplasms, con® rming that they represent
morphological variations of the same entity. CD117
positive tumours were also positive for CD34 in
72% of cases, while the (poorly speci® c) neural
marker PGP9.5 was positive in about 70% of cases
and smooth muscle actin was positive in 15± 30% of
cases.
10,31 Interestingly, all tumours showing im-
munohistochemical evidence of smooth muscle dif-
ferentiation, i.e. desmin positivity and/or diffuse
actin positivity, failed to stain for CD117, further
justifying the separation of GISTs and conventional
smooth muscle tumours in this anatomical location.
These ® ndings have led to a unifying concept, re-
garding GISTs as a morphologically (and im-
munophenotypically) heterogeneous group of
tumours differentiating towards an ICC phenotype.
The signi® cance of CD34 negativity in a subset of
these tumours, more often malignant in Sarlomo-
Rikala’s study,
11 is unclear, but a parallel has been
made by Kindblom et al. with the variable im-
munophenotypes seen in the different subtypes of
ICC.
10 GANTs, which, in our experience, are usu-
ally immunoreactive for CD117 but negative for
CD34, could correspond to this subset of CD34
negative tumours and represent a distinctive group
within the spectrum of GISTs.
As discussed above, the interpretation and com-
parison of most previous studies has been impaired
by the lack of consistency in the de® nition of GISTs
and therefore in the criteria for inclusion. The
recognition of GISTs as a cohesive but phenotypi-
cally heterogeneous group of tumours, de® ned by
the expression of c-Kit, and their more objective
separation from other mesenchymal neoplasms
(mostly true smooth muscle tumours) will certainly
allow more reproducibility between studies and
could help to re® ne our criteria for malignancy
and/or prognostic factors. The expression of c-Kit
also appears as a useful adjunct in the diagnosis of
those GISTs arising in less usual sites, such as the
mesentery, omentum or retroperitoneum, as well as
in their separation from other intraabdominal neo-
plasms, such as desmoid ® bromatosis for spindle
cell lesions, and melanoma or metastatic car-
cinomas, which may be confused with epithelioid
GISTs.
The similarity between the ultrastructural features
of ICC and GIST, in Kindblom’s study, not only
provided further evidence for an ICC phenotype but
also represents a rational explanation for the contro-
versial results of early electron microscope studies.
Ultrastructural characteristics shared by ICC and
GISTs included incomplete features of myoid dif-
ferentiation, such as networks of intermediate
® laments, including occasional bundles of actin-type
® laments or incomplete external lamina, as well as
neurogenic features such as long interdigitating pro-
cesses, occasional gap and desmosome-like junc-
tions or synapse-like contacts.
10 This coexistence of
myoid and neurogenic features probably explains
the `hesitations’ between smooth-muscle and nerve
sheath or neural differentiation in previous studies.
Ultrastructural features of GANT (long cytoplasmic
processes and synapse-like junctions with dense-
core granules) were also part of this spectrum.
10,41
c-Kit mutations had already been demonstrated in
human malignant mastocytosis
69,70 and transfection
of the mutant c-Kit complementary DNA into
murine lymphoid cells has induced their auton-
omous growth.
9,71 The possibility that c-Kit might
play some central role in tumour development or
progression has recently received additional support,
with the identi® cation of a germline mutation in a
family with multiple GISTs, in the same domain
where mutations had been found in sporadic cases.
Future investigations in such patients might there-
fore provide valuable information concerning the
biology of GISTs. Losses in the long arm of chro-
mosome 14, identi® ed by one group using compara-
tive genomic hybridization,
72 as well as the few
reported karyotypic changes, including structural
monosomies of chromosomes 14 and 22,
73,74 might
also serve as the basis for further investigations.
Study of cases arising in the setting of the CarneyGI stromal tumours 139
syndrome could also possibly generate genetic infor-
mation that might help in better understanding
sporadic cases.
Conclusions
The two fundamental issues concerning GISTs, i.e.
their phenotype and prediction of behaviour, had
already been stressed by Stout and collaborators in
their early description of stromal neoplasms of the
gut in 1941. More than ® fty years later, the probable
differentiation of GISTs towards an interstitial cell
of Cajal phenotype could well represent, at last, an
elegant answer to the ® rst question. Although the
implications of c-Kit mutations in the pathogenesis
of GISTs need to be further investigated, these
molecular ® ndings possibly represent the ® rst step
towards understanding the biology of these enig-
matic tumours. Furthermore, the availability of re-
liable molecular and immunohistochemical
signatures of GIST has already helped to clarify the
extent of this spectrum, allowing more accurate
distinction of GIST from other mesenchymal neo-
plasms of the gut, such as `true’ leiomyomas,
leiomyosarcomas or nerve sheath tumours.
However, at the present time, the reliable distinc-
tion of benign from malignant GISTs remains a
challenge. None of the multiple prognostic factors
identi® ed had proved to be reliable in the evaluation
of individual cases and multifactorial approaches
have thus far failed to improve signi® cantly upon
our morphological classi® cation of GISTs. Hope-
fully, the recent ® ndings relating to c-Kit mutations
might improve our understanding of the enigmatic
biology of GISTs in the near future and should
improve the coherence of future clinical and patho-
logical studies aiming at re® ning our prognostic
criteria and classi® cation schemes.
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